Retrophin to Present at the Leerink Partners 4th Annual Rare Disease Roundtable

SAN DIEGO, Sept. 16, 2015 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Dr. Alvin Shih, Executive Vice President and Head of Research and Development, will present at the Leerink Partners 4th Annual Rare Disease Roundtable in New York City on Wednesday, September 30, 2015 at 8:50 a.m. ET.

A live webcast will be available at in the Events & Presentations section. A replay of the webcast will be archived on the Retrophin website and remain accessible for at least 30 days.

About Retrophin

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam®, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), infantile spasms, nephrotic syndrome and others. For additional information, please visit

Contact: Retrophin, Inc. Chris Cline, CFA Director, Investor Relations 646-564-3680

Source:Retrophin, Inc.